Latest from Mayo Clinic Cancer Center

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the FDA approval of lenvatinib (Lenvima) as a frontline systemic treatment for patients with advanced hepatocellular carcinoma (HCC).
Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the evolution of treatment for patients with pancreatic cancer.
 
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer. 
Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.
 
Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.
 
Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses adjuvant therapy in pancreatic cancer.
Steven M. Ansell, MD, PhD, discusses the efficacy of PD-L1 blockade in Hodgkin lymphoma, patient treatment that has encouraged him to look for deeper solutions, alternative drug combinations that appear to be making headway, and potential avenues of discovery for the future.
Publication Bottom Border
Border Publication
x